Andelyn Biosciences and South Korea-based ENCell signed a collaboration to create a manufacturing bridge between the U.S. and Asia-Pacific. The companies positioned the agreement as a dual-hemisphere workflow intended to reduce regulatory and logistical friction when moving programs across regions. The collaboration is designed to support in-country manufacturing for in-country clinical trials, aiming to shorten lead times and improve supply-chain responsiveness for viral-vector gene therapy programs. With cell and gene therapy developers increasingly seeking scalable, regionally compliant manufacturing footprints, the U.S.–APAC linkage targets one of the main constraints on global CGT expansion.